Behavioral deficit and decreased GABA receptor functional regulation in the cerebellum of epileptic rats: effect of Bacopa monnieri and bacoside A.
In the present study, the effects of Bacopa monnieri and its active component, bacoside A, on motor deficit and alterations of GABA receptor functional regulation in the cerebellum of epileptic rats were investigated. Scatchard analysis of [(3)H]GABA and [(3)H]bicuculline in the cerebellum of epileptic rats revealed a significant decrease in B(max) compared with control. Real-time polymerase chain reaction amplification of GABA(A) receptor subunits-GABA(Aalpha1), GABA(Aalpha5,) and GABA(Adelta)-was downregulated (P<0.001) in the cerebellum of epileptic rats compared with control rats. Epileptic rats exhibit deficits in radial arm and Y-maze performance. Treatment with B. monnieri and bacoside A reversed these changes to near-control levels. Our results suggest that changes in GABAergic activity, motor learning, and memory deficit are induced by the occurrence of repetitive seizures. Treatment with B. monnieri and bacoside A prevents the occurrence of seizures thereby reducing the impairment of GABAergic activity, motor learning, and memory deficit.
Mathew
Jobin
J
Department of Biotechnology, Molecular Neurobiology and Cell Biology Unit, Centre for Neuroscience, Cochin University of Science and Technology, Kerala, India.
Peeyush Kumar
T
T
Khan
Reas S
RS
Paulose
C S
CS
D000818:Animals; D000927:Anticonvulsants / Q000627:therapeutic use; D001526:Behavioral Symptoms / Q000188:drug therapy / Q000209:etiology; D001640:Bicuculline / Q000493:pharmacokinetics; D002220:Carbamazepine / Q000627:therapeutic use; D002531:Cerebellum / Q000187:drug effects*; D004195:Disease Models, Animal; D004827:Epilepsy / Q000139:chemically induced / Q000150:complications* / Q000188:drug therapy / Q000473:pathology*; D018756:GABA Antagonists / Q000493:pharmacokinetics; D008297:Male; D018782:Maze Learning / Q000187:drug effects; D008517:Phytotherapy / Q000379:methods*; D010862:Pilocarpine; D028321:Plant Preparations / Q000627:therapeutic use*; D011485:Protein Binding / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D018079:Receptors, GABA / Q000378:metabolism*; D012503:Saponins / Q000627:therapeutic use*; D014315:Triterpenes / Q000627:therapeutic use*; D014316:Tritium / Q000493:pharmacokinetics; D005680:gamma-Aminobutyric Acid / Q000493:pharmacokinetics
D000927:Anticonvulsants; D018756:GABA Antagonists; D028321:Plant Preparations; D018079:Receptors, GABA; D012503:Saponins; D014315:Triterpenes; C500175:bacoside A; D010862:Pilocarpine; D014316:Tritium; D002220:Carbamazepine; D005680:gamma-Aminobutyric Acid; D001640:Bicuculline